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SUMMARY
We performed a meta-analysis to evaluate the association between ABCB1 C3435T polymorphisms and the
prevalence of epilepsy, including all relevant human
studies (until June 2009), in which patients with or without epilepsy had undergone genotyping for the ABCB1
gene. Odds ratios (ORs) were calculated using a random effects model. We identified 9 case–control studies

Epilepsy affects 0.5–2.0% of the general population
(Lakhan et al., 2009). It carries significant morbidity and
mortality, and has significant implications on society at
large. About one-third of patients with epilepsy have poor
seizure-control and experience recurrent seizures despite
seemingly appropriate therapy (Sills et al., 2005).
It has been recently suggested that polymorphisms of the
ABCB1 C3435T gene, and more specifically, the ABCB1
3435CC genotype, may be associated with a predisposition
to develop epilepsy (Hung et al., 2005; Ebid et al., 2007),
and can, therefore, identify high-risk groups for the
disease. In addition, it has been suggested (Buono et al.,
2006) that haplotypes of two markers in the ABCB1 gene,
at positions 1236 and 3435, were associated with epilepsy
susceptibility.
The ABCB1 gene encodes for p-glycoprotein (also known
as MDR1), which is expressed in organs and tissues with
excretory functions at the blood–tissue barrier, thereby
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that included a total of 3,996 patients (2,454 with epilepsy and 1,542 nonepileptic subjects). No association
was found between ABCB1 C3435T polymorphisms
and the risk of having epilepsy (odds ratio 1.07, 95%
confidence interval 0.76–1.51; p = 0.34). ABCB1 genotyping for epileptic patients is not warranted.
KEY WORDS: MDR1, ABCB1 C3435T, Epilepsy, Polymorphism, Meta-analysis.

protecting them from xenobiotics. The function of p-glycoprotein can be influenced by polymorphisms in the encoding
gene, ABCB1 (Sills et al., 2005). A synonymous C to T
transformation at position 3435 of exon 26 is one common
polymorphism of the ABCB1 gene. This single nucleotide
polymorphism (SNP) has been suggested to decrease the
expression of the gene, and individuals with the TT genotype have decreased MDR1 functional expression compared
to the C/C homozygotes (Sills et al., 2005).
The aim of the present study was to investigate whether
certain polymorphic alleles of the ABCB1 C3435T are more
prevalent in epileptic patients versus nonepileptic subjects,
and whether this gene may serve as a biomarker for a
tendency to develop epilepsy.

Methods
We conducted a systematic review and meta-analysis to
address the hypothesis that polymorphisms in the ABCB1
gene are associated with increased prevalence of epilepsy.
We searched MEDLINE and EMBASE to identify all
relevant published human case–control or cohort studies
that reported the proportion of the MDR1/ABCB1 C3435T
(rs1045642) [Database of Single Nucleotide Polymorphisms (dbSNP), 2007] genotypes among patients with epilepsy and control (nonepileptic) subjects from January 1966
to June 2009. Relevant articles were retrieved with no language restrictions. The Boolean search strategy ‘‘epilepsy
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and (MDR1 or ABCB1 or C3435T or p-glycoprotein)’’ was
used. Once all relevant articles were compiled, their reference lists were reviewed manually by an experienced
researcher for additional sources. In addition, we searched
Web of Knowledge and Scopus conference proceedings,
using a similar search strategy, in order to retrieve all relevant unpublished studies and scientific meeting abstracts.
Two experienced investigators acted as reviewers, independently selecting studies for inclusion in the meta-analysis
based on the inclusion criteria described and a standardized
checklist. For all relevant sources, data were extracted from
the results section and placed into contingency tables. Prevalence of homozygous ABCB1 3435CC was compared to
prevalence of homozygous ABCB1 3435TT (Siddiqui et al.,
2003). The extracted data were entered into Cochrane’s
Review Manager Software (version 4.1; Cochrane Collaboration, Oxford, United Kingdom). Individual and summary
odds ratios (ORs) and 95% confidence intervals (CIs) were
calculated using a random effects model (Bournissen et al.,
2009). Included studies were tested for heterogeneity using
the chi-square test and the I2. Publication bias was assessed
by visual inspection of the funnel plot (effect size vs. study
size). To test the robustness of our findings, we also performed a cumulative meta-analysis (Bournissen et al.,
2009), by sequentially adding studies to the meta-analysis in
chronological order, using a random effects model. Publication bias was assessed by visual inspection of the funnel plot
(effect size vs. study size).

Results
We identified nine relevant studies; all were observational case–control studies that reported on ABCB1 C3435T
allele frequencies in epileptic versus nonepileptic subjects
(Table 1). A total of 3,996 subjects were included in the
nine studies, including 2,454 patients with epilepsy and
1,542 nonepileptic subjects.
We found no statistical significance between the prevalence of the homozygous ABCB1 3435CC genotype compared to the homozygous ABCB1 3435TT genotype in
epileptic versus nonepileptic patients (OR 1.07, 95% CI
0.76 – 1.51; Fig. 1). The cumulative meta-analysis indicates
that as early as 2006, with the publication of the third study,
we would have identified no association between the
ABCB1 polymorphism and the risk to develop epilepsy
(supplementary Fig. S1).
The included studies reported genetic data from various
geographic areas including four from Europe, two from Turkey (Dericioglu et al., 2008; Ozgon et al., 2008), one from
the United Kingdom (Siddiqui et al., 2003), and one from
Germany (Ufer et al., 2009). Three studies were performed
in East Asia: Taiwan (Hung et al., 2005), Korea (Kim et al.,
2006), and China (Kwan et al., 2007); one study was
performed in Egypt (Ebid et al., 2007) and one in India
(Lakhan et al., 2009). Data on genotypes from additional

Table 1. Random effects prevalence of ABCB1 3435
CC versus TT in patients with epilepsy versus
nonepileptic subjects (nine studies)

Siddiqui et al. (2003)
Hung et al. (2005)
Kim et al. (2006)
Ebid et al. (2007)
Kwan et al. (2007)
Dericioglu et al. (2008)
Ozgon et al. (2008)
Lakhan et al. (2009)
Ufer et al. (2009)

OR

Lower 95%

Upper 95%

1.27
1.90
0.68
2.46
0.90
0.93
2.05
0.53
0.71

0.74
1.22
0.38
0.95
0.51
0.43
0.95
0.28
0.44

2.18
2.98
1.20
6.32
1.58
2.00
4.42
0.99
1.16

Summary OR 1.07, 95% CI 0.76–1.51).
CI, confidence interval. OR, odds ratio.

markers in the ABCB1 gene were not prevalent in the literature to allow haplotype analysis.

Discussion
This meta-analysis of observational studies, which
included 3,996 patients, failed to show an association
between ABCB1 C3435T genotypes and predisposition to
epilepsy.
Several researchers have focused on the potential role of
the ABCB1 gene in drug resistance to anticonvulsant therapy (Siddiqui et al., 2003; Hung et al., 2005; Sills et al.,
2005; Kim et al., 2006; Kwan et al., 2007), a serious problem associated with increased morbidity and mortality from
epilepsy. The ABCB1 gene encodes for p-glycoprotein,
which is expressed in organs with excretory functions at the
blood–tissue barrier. P-Glycoprotein operates as a multidrug efflux pump, extruding xenobiotics from mammalian
brain tissue, and acting as a natural defence mechanism
(Dericioglu et al., 2008). It has been speculated that polymorphisms in the ABCB1 gene, specifically the 3435CC
genotype, are associated with drug resistance to anticonvulsants (Siddiqui et al., 2003), and may provide a biologically
plausible explanation for this common phenomenon. However, subsequent studies have provided conflicting results
and failed to replicate the original findings. In addition, concerns have been raised in multiple studies that results may
depend on ethnic background of study subjects. To address
these questions, we recently performed a meta-analysis
(Bournissen et al., 2009) of all relevant studies (n = 3,371
patients: 1,646 with drug-resistant epilepsy and 1,725 with
drug-responsive epilepsy) and showed that the polymorphisms at the ABCB1 C3435T gene are not associated with
anticonvulsant drug resistance. These results remained stable when we stratified patients by ethnicity.
Previous authors who suggested that an association
between the ABCB1 gene and the development of epilepsy
(as opposed to drug resistance) may exist (Hung et al.,
2005; Buono et al., 2006; Ebid et al., 2007) have not
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Figure 1.
Prevalence (OR) of ABCB1 3435 CC versus TT genotypes in patients with epilepsy versus nonepileptic subjects.
Epilepsia ILAE

provided a biologically plausible or a mechanistic explanation for their hypothesis.
We did not perform a subanalysis of subjects by ethnic
background, as we deemed it unnecessary, since only a single study (Hung et al., 2005) clearly supported an association between the ABCB1 3435CC genotype and an
increased risk for epilepsy.
This meta-analysis provides further evidence that
although the ABCB1 gene has been highly investigated and
plays many important roles, it is unlikely that the polymorphism at 3435 plays a major role in the development of epilepsy or in drug resistance to anticonvulsants. It is,
therefore, not recommended that patients be tested for the
C3435T polymorphisms of the ABCB1 gene in this context,
as such testing is unlikely to yield any information that
would be useful in the diagnosis, management, or prognosis
of epilepsy. It remains to be determined whether haplotypes
in the ABCB1 gene play a role in epilepsy susceptibility or
anticonvulsant drug resistance.
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